Proposed changes to appeal period for technology appraisal and highly specialised technologies appeals Methods / process manual consultation NICE process and methods 16 February 2025 Spesolimab for ...

People in England to benefit from groundbreaking one-off gene therapy for severe sickle cell disease approved by NICE ...

The treatment is recommended for people aged 12 to 65 who have moderate to severe and persistent allergic rhinitis and have been diagnosed through clinical history and a positive test of their house ...

New and innovative mechanisms of action are constantly being discovered and developed into medicines that tackle a broad ...

NICE, in collaboration with other international health technology assessment agencies, has published a new report which ...

This indicator covers the incidence of healthcare associated infections from Methicillin-resistant Staphylococcus aureus (MRSA). It measures outcomes that reflect the quality of care or processes ...

Healthcare professionals should consider asking people about gambling when speaking to them about smoking and alcohol consumption during a health check or GP appointment, new guidance recommends.

This indicator covers under 75 mortality from respiratory disease. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator will be ...

This indicator will be reviewed using the assessment criteria in appendix B of the NICE indicators process guide when it reaches its review date or the underlying guidance is updated.

For further information on the guideline development process, please see how we develop NICE guidelines ...

Provide resuscitation and immediate emergency treatment for children, young people and adults who have convulsive status epilepticus (seizures lasting 5 minutes or more). If the person with convulsive ...

For a short explanation of why the committee made this recommendation for research, see the rationale section on treatment strategies for non-proliferative and proliferative diabetic retinopathy .